Amarin Corp Plc (AMRN)

[Whalatane]

N7. yes you're out of your mind expecting $20-$30 a share ...well U asked :--)

Most of the ROW can't afford Vascepa . Poland ...where the 40% of the males have a CV event before age 50 probably can't afford it either ...and they are roughly 40m people in the EU

So we have a rich country drug where cost effectiveness will be judged against that countries costs of Cath labs, angiograms , stenting and CABG.
So Vascepa will be cost effective for at least secondary prevent in Germany , France , UK etc . Most of the health care is govt run in these countries ...so Vascepa has to be cost effective.

Vascepa definitely has a market there but suggest you cut your expectations in half ...and allow several years .
Sorry ...JMO
Kiwi